Valuation : Cyclopharm Limited

Market Cap 64.75M 46.46M 40.03M 37.53M 34.26M 64.55M 4.44B 445M 174M 2.24B 174M 171M 7.43B P/E 2026 *
-3.74x
P/E 2027 * -5.86x
Enterprise Value 64.75M 46.46M 40.03M 37.53M 34.26M 64.55M 4.44B 445M 174M 2.24B 174M 171M 7.43B EV / Sales 2026 *
1.74x
EV / Sales 2027 * 1.37x
Free-Float
58.05%
Yield 2026 *
-
Yield 2027 * -
1 day+0.98%
1 week+4.04%
Current month-11.97%
1 month-0.96%
3 months-26.43%
6 months-39.05%
Current year-47.45%
1 week 0.5
Extreme 0.505
0.53
1 month 0.46
Extreme 0.465
0.6
Current year 0.45
Extreme 0.45
1.29
1 year 0.45
Extreme 0.45
1.29
3 years 0.45
Extreme 0.45
3.15
5 years 0.45
Extreme 0.45
3.15
10 years 0.45
Extreme 0.45
3.45
Manager TitleAgeSince
Chief Executive Officer 60 2009-10-20
Director of Finance/CFO - 2024-02-25
Chief Operating Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 60 2008-06-02
Director/Board Member 65 2021-08-09
Director/Board Member - 2022-08-31
Date Insider Type Main position Quantity % Market Cap.
3/12/26 Buy

Director

21,052 0.0175%
3/12/26 Buy

Director

5,263 0.0044%
3/12/26 Buy

Director

21,052 0.0175%
Change 5-day change 1-year change 3-year change Capi.($)
+0.98%+4.04%-48.50%-79.23% 46.13M
-1.35%-1.13%+27.04%+14.12% 233B
+0.18%-1.27%+5.25%-17.37% 152B
+1.51%-1.64%-21.37%+23.59% 130B
+0.36%-7.01%-55.71%-12.92% 67.64B
+0.29%+0.47%+11.06%+18.65% 51.85B
+0.66%-1.69%-16.57%-13.62% 50.91B
-2.44%-3.25%+23.11%+28.29% 44.46B
-1.56%+0.97%+39.32%+47.34% 41.39B
-5.31%-1.74%+117.39%+36.28% 34.38B
Average -0.69%-0.28%+8.10%+4.51% 80.52B
Weighted average by Cap. -0.48%-1.49%+8.67%+9.41%

Financials

2026 *2027 *
Net sales 37.2M 26.69M 23M 21.56M 19.68M 37.08M 2.55B 256M 99.82M 1.29B 100M 98.03M 4.27B 47.2M 33.86M 29.18M 27.36M 24.98M 47.05M 3.24B 325M 127M 1.63B 127M 124M 5.42B
Net income -17.4M -12.48M -10.76M -10.09M -9.21M -17.34M -1.19B -120M -46.69M -602M -46.87M -45.85M -2B -12.4M -8.9M -7.67M -7.19M -6.56M -12.36M -850M -85.28M -33.27M -429M -33.4M -32.68M -1.42B
Net Debt - -
Logo Cyclopharm Limited
Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its Technegas product is a broad-spectrum diagnostic lung imaging technology for visualization of pulmonary ventilation and lung function. It includes the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. Company distributes its products in approximately 65 countries.
Employees
104
Date Price Change Volume
26-08-28 A$0.5150 +0.98% 7,614
26-08-27 A$0.5100 -1.92% 45,681
26-08-26 A$0.5200 +1.96% 26,520
26-08-25 A$0.5100 +0.99% 6,076
26-08-24 A$0.5050 +2.02% 11,842
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3695USD
Average target price
0.7170USD
Spread / Average Target
+94.05%

Quarterly revenue - Rate of surprise